The Phase 3 study (NCT05468489) evaluating atezolizumab plus chemotherapy against serplulimab plus chemotherapy in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) reached its primary completion on 2026-02-28. This trial aims to compare the efficacy and safety of these two regimens in previously untreated US patients.
Background
Atezolizumab (Tecentriq) is an established immunotherapy. This trial focuses on Extensive Stage Small Cell Lung Cancer (ES-SCLC), a challenging malignancy.
Trial design
The Phase 3 study, NCT05468489, is a randomized, open-label trial designed to evaluate treatments for Extensive Stage Small Cell Lung Cancer (ES-SCLC). It enrolled 200 participants in the US who were previously untreated for their condition. The study compares two treatment arms: serplulimab plus chemotherapy (carboplatin-etoposide) against atezolizumab plus chemotherapy (carboplatin-etoposide), with participants randomized at a 1:1 ratio.
What this means
The primary completion of this Phase 3 trial indicates that data collection for the study's primary objectives is complete. The trial's findings, once available, will provide important comparative data on the efficacy and safety of atezolizumab versus serplulimab, both in combination with chemotherapy, for patients with ES-SCLC. These results could inform future treatment strategies for this patient population.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05468489, titled "To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC," was posted on 2026-02-28 on clinicaltrials.gov.